(Total Views: 389)
Posted On: 06/10/2019 5:51:28 PM
Post# of 72443
The market cap for an eyewash company is higher than the market cap for IPIX, which is not a one-trick pony like NBY. In the long term, which has better prospects, an eyewash company (which will have competitors soon) or an antibacterial and anti-inflammatory drug company than may have a cure for cancer?
IPIX market cap: 46.305 Million
pipeline: Brilacidin for Oral Mucositis, various types of IBD, other possible applications for infection and inflammation, and possible cure for cancer.
NBY market cap: 58.876 Million
pipeline: anti-bacterial eyewash, over the counter.
NWBO market cap: 157.433 million
Pipeline: cancer "vaccine" -- similar to others, many of which failed and/or caused life-threatening side effects.
It should be evident that the upside for IPIX is massive. It should be at least comparable right now to the market cap of NWBO, which has one very risky technology.
IPIX market cap: 46.305 Million
pipeline: Brilacidin for Oral Mucositis, various types of IBD, other possible applications for infection and inflammation, and possible cure for cancer.
NBY market cap: 58.876 Million
pipeline: anti-bacterial eyewash, over the counter.
NWBO market cap: 157.433 million
Pipeline: cancer "vaccine" -- similar to others, many of which failed and/or caused life-threatening side effects.
It should be evident that the upside for IPIX is massive. It should be at least comparable right now to the market cap of NWBO, which has one very risky technology.
(7)
(0)Scroll down for more posts ▼
